Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
10.15430/JCP.2015.20.2.113
- Author:
Eric DI LUCCIO
1
Author Information
1. School of Applied Biosciences, Kyungpook National University, Daegu, Korea. diluccio@knu.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Epigenomics;
Drug design;
Histone-Lysine N-Methyltransferase;
NSD2 protein;
Antagonists & inhibitors
- MeSH:
Biology;
Chemistry;
Drug Design;
Epigenomics*;
Hematologic Neoplasms;
Histone-Lysine N-Methyltransferase;
Histones;
Humans;
Inhibitory Concentration 50;
Lymphoma, Non-Hodgkin;
Lysine;
Mass Screening;
Methylation;
Models, Molecular;
Multiple Myeloma;
Prognosis;
Structure-Activity Relationship;
United States
- From:Journal of Cancer Prevention
2015;20(2):113-120
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Multiple myeloma SET domain (MMSET)/nuclear receptor binding SET domain 2 (NSD2) is a lysine histone methyltransferase (HMTase) and bona fide oncoprotein found aberrantly expressed in several cancers, suggesting potential role for novel therapeutic strategies. In particular, MMSET/NSD2 is emerging as a target for therapeutic interventions against multiple myeloma, especially t(4;14) myeloma that is associated with a significantly worse prognosis than other biological subgroups. Multiple myeloma is the second most common hematological malignancy in the United States, after non-Hodgkin lymphoma and remains an incurable malignancy. Thus, effective therapeutic strategies are greatly needed. HMTases inhibitors are scarce and no NSDs inhibitors have been isolated. METHODS: We used homology modeling, molecular modeling simulations, virtual ligand screening, computational chemistry software for structure-activity relationship and performed in vitro H3K36 histone lysine methylation inhibitory assay using recombinant human NSD2-SET and human H3.1 histone. RESULTS: Here, we report the discovery of LEM-06, a hit small molecule inhibitor of NSD2, with an IC50 of 0.8 mM against H3K36 methylation in vitro. CONCLUSIONS: We propose LEM-06 as a hit inhibitor that is useful to further optimize for exploring the biology of NSD2. LEM-06 derivatives may pave the way to specific NSD2 inhibitors suitable for therapeutic efforts against malignancies.
